[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100457909":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":37,"responsibleParty":57,"collaborators":10,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":10,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Abramson Cancer Center at Penn Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Metastatic prostate cancer",null,"Men at least 18 years of age with metastatic prostate cancer may be eligible for this study .Volunteers that meet the eligibility criteria will be considered for study participation regardless of race or ethnic background. Only individuals who can understand and give informed consent will be eligible to participate in this study.",[13],"Drug: [18F]FluorThanatrace",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","[18F]FluorThanatrace","Investigational radiopharmaceutical used with Positron Emission Tomography (PET\u002FCT) imaging that may provide a non-invasive measurement of PARP-1 expression",[9],[21],"[18F]FTT",[23],{"name":24,"affiliation":25,"role":26},"Neil Taunk, MD","University of Pennsylvania","PRINCIPAL_INVESTIGATOR",[28,33],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Erin Schubert, BA","CONTACT","215-573-6569","erin.schubert@pennmedicine.upenn.edu",{"name":34,"role":30,"phone":35,"phoneExt":10,"email":36},"Ashley Veronsky, BA","215-898-4346","ashley.veronsky@pennmedicine.upenn.edu",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"University of Pennsylvania Hospital","RECRUITING","Philadelphia","Pennsylvania","19104","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-75.16362,39.95238,{"lat":50,"lon":49},[53,56],{"name":54,"role":30,"phone":31,"phoneExt":55,"email":32},"Erin Schubert","2155736569",{"name":24,"role":26,"phone":10,"phoneExt":10,"email":10},{"type":58,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100457909","ftt-petct-in-metastatic-prostate-cancer-100457909",false,"NCT05242744","FTT PET\u002FCT in Metastatic Prostate Cancer","Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET\u002FCT) in Patients With Metastatic Prostate Cancer","Inclusion Criteria:\n\n1. Participants will be ≥ 18 years of age\n2. Histologically proven prostate carcinoma\n3. Clinical evidence of metastatic disease with at least one lesion identified on standard of care imaging (CT, MRI, Bone Scan, FDG or other PET\u002FCT, Ultrasound)\n4. Considered a candidate for new therapy or change in therapy with PARP inhibitor therapy and\u002For androgen deprivation therapy (ADT) and\u002For chemotherapy with or without additional agents, either on a clinical trial or as part of clinical care.\n5. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.\n\nExclusion Criteria:\n\n1. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician\n2. Any current medical condition, illness, or disorder as assessed by medical record review and\u002For self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study","MALE","18 Years",{"count":69,"type":70},30,"ESTIMATED","OBSERVATIONAL","Up to 30 men with metastatic prostate cancer will undergo up to 2 FTT PET\u002FCT scans to look at PARP activity in sites of known cancer. Subjects will undergo a baseline scan prior to starting new therapy and a second, optional, post-therapy scan 1-21 days after the start of treatment. Tissue from a clinical or research biopsy will be compared to imaging measures, if available.",[74],"Prostate Cancer Metastatic",[76,77],"PET\u002FCT","PARP inhibitor","2026-06-24",{"date":80,"type":81},"2026-06-26","ACTUAL",{"date":83,"type":81},"2023-03-01",{"date":85,"type":70},"2027-07",{"name":5,"class":6},1]